Intuitive Surgical Inc

Latest Report Overview

Intuitive Surgical Inc (ISRG) reported For the quarterly period ended June 30, 2026 (Issuer fiscal Q2 FY2026) revenue of $2,892 million with diluted EPS of $2.29 and net income of $818 million. Operating margin was 33.6%, and free cash flow was $948 million for the period. Management highlighted the continued success of the da Vinci platform and growth in the Ion endoluminal system. The company maintains a strong liquidity position, supported by disciplined capital allocation, including ongoing research and development investments and periodic share repurchases. Strategic initiatives remain focused on expanding clinical indications and enhancing the surgical ecosystem to drive long-term adoption. The company's outlook emphasizes the durability of its installed base and the expanding role of robotic surgery in standard clinical practice. Management continues to monitor macroeconomic and supply chain factors, while executing on its strategy to integrate digital surgery and AI-driven insights into the da Vinci platform to further solidify its competitive position and clinical value proposition.

Key Takeaways for Intuitive Surgical Inc

• Revenue growth in Q2 2026 reached 18.5% YoY to $2,892.3 million, driven by robust procedure volumes across key specialties.
• Gross margins remain resilient at 67.8%, reflecting the company's high-margin, recurring revenue model tied to instruments and accessories.
• The installed base continues to grow, reinforcing long-term switching costs and deepening the company's clinical penetration.
• Strategic capital allocation remains a priority, with $254.7 million in common stock repurchased during the second quarter of 2026.
• Operational execution remains solid despite global geopolitical and supply chain uncertainties mentioned in recent filings.
• The company's focus on Ion endoluminal system adoption provides a significant long-term growth driver, complementing the established da Vinci business.
• Regulatory risk remains a critical watchpoint, as the company requires continuous clearances to enter new markets or expand indications.

What Does Intuitive Surgical Inc Do?

Intuitive Surgical, Inc. is a leader in robotic-assisted, minimally invasive surgery. The company develops, manufactures, and markets the da Vinci surgical system, a sophisticated robotic platform consisting of a surgeon console, patient-side cart, and high-performance vision system. Additionally, the company markets the Ion endoluminal system, a flexible, robotic-assisted platform primarily used for minimally invasive lung biopsies. The company's customers primarily include hospitals, surgery centers, and healthcare providers globally, covering specialties such as urology, gynecology, cardiothoracic surgery, and general surgery. With a large and growing global installed base of systems, Intuitive Surgical employs a recurring revenue model where the initial sale of a capital system is supplemented by long-term sales of instruments, accessories, and maintenance services, which are critical to the system's ongoing operation.

Growth Drivers for Intuitive Surgical Inc

• Continued adoption and expansion of the da Vinci system across various surgical specialties and global markets.
• Increased utilization and 'menu' of surgical procedures that can be performed robotically, supported by ongoing surgeon training programs.
• Successful penetration and expansion of the Ion endoluminal system in the bronchoscopy and lung biopsy markets.
• Ongoing investment in digital surgery and AI integration to improve clinical outcomes and operational efficiency for hospital customers.
• Expansion of the installed base in international markets, particularly in under-penetrated emerging regions.